BioCentury
ARTICLE | Financial News

Antibacterial company Entasis proposes NASDAQ IPO

August 17, 2018 11:51 PM UTC

Entasis Therapeutics Inc. (Waltham, Mass.) proposed on Friday to raise $86.3 million in an IPO on NASDAQ underwritten by Credit Suisse, BMO Capital Markets, SunTrust Robinson Humphrey and Wedbush PacGrow.

In September, the antibacterial company raised $31.9 million in a series B-1 extension with participation from new investors Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech. At the time, Entasis said it expected the funds to take its lead compound all the way through commercialization and to move two others to their next milestones (see "Antibiotic Engine")...